{'fraction_non_alphanumeric': 0.02329450915141431, 'fraction_numerical': 0.004991680532445923, 'mean_word_length': 6.432098765432099, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A cost effectiveness analysis of thiopurine methyltransferase testing for guiding 6‐mercaptopurine dosing in children with acute lymphoblastic leukemia

An increased understanding of the genetic basis of disease creates a demand for personalized medicine and more genetic testing for diagnosis and treatment. The objective was to assess the incremental cost‐effectiveness per life‐month gained of thiopurine methyltransferase (TPMT) genotyping to guide doses of 6‐mercaptopurine (6‐MP) in children with acute lymphoblastic leukemia (ALL) compared to enzymatic testing and standard weight‐based dosing.